Breaking News

AMRI Names Asian Ops VP

February 25, 2013

Yura to head discovery and development services

Takeshi Yura, Ph.D., has been appointed vice president of Discovery and Development Services, Asia. Dr. Yura will report directly to AMRI’s chairman, president and chief executive officer Thomas E. D'Ambra, Ph.D. Dr. Yura has also assumed leadership of AMRI's Discovery and Development efforts at the company’s Hyderabad, India site.
 
Dr. Yura joined the company in January 2011 and most recently served as senior director of Drug Discovery services in Singapore, leading the chemistry and biology teams for integrated drug discovery operations in Asia. Dr. Yura has more than 22 years of scientific and leadership experience in discovery research, project management and business development. Before joining the company he was a director at Dishman Japan Ltd., responsible for sales and all business development activities for contract manufacturing services. He has also served as discovery chemistry research head at Pfizer Japan and section head, medicinal chemistry at Bayer Yakuhin in Japan.
 
Dr. D'Ambra said, "AMRI's Singapore and Hyderabad operations are important and growing businesses for AMRI and conduct projects for customers located all over the world. With the ongoing evolution of outsourcing and a growing focus from customers on strategic relationships, we believe that Dr. Yura's leadership, his focus on excellence in scientific research and his dedication to quality and the integrity of our customers' intellectual property will provide integration under one leadership of what we are referring to as 'AMRI Asia.' This new alignment will enable seamless transfer and execution of projects within and between sites to consistent high standards and provide more effective project management and development of key talent."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important